S'abonner

Risks of adverse obstetric outcomes among female survivors of adolescent and young adult cancer in England (TYACSS): a population-based, retrospective cohort study - 30/07/24

Doi : 10.1016/S1470-2045(24)00269-9 
Ceren Sunguc, PhD a, David L Winter, HNC a, Emma J Heymer, PhD a, Gavin Rudge, MSc a, Angela Polanco, PhD b, Katherine A Birchenall, PhD c, Melanie Griffin, MD c, Richard A Anderson, ProfMD d, W Hamish B Wallace, ProfMD e, Michael M Hawkins, ProfDPhil a, Raoul C Reulen, PhD a,
a Centre for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, UK 
b National Institute for Health Research, London, UK 
c Department of Obstetrics and Gynaecology, St Michael’s Hospital, Bristol, UK 
d Centre for Reproductive Health, Institute for Repair and Regeneration, University of Edinburgh, Edinburgh, UK 
e Department of Paediatric Haematology and Oncology, Royal Hospital for Children and Young People, Edinburgh, UK 

* Correspondence to: Dr Raoul C Reulen, Centre for Childhood Cancer Survivor Studies, University of Birmingham, College of Medical and Dental Sciences, Institute of Applied Health Research, Birmingham B15 2TT, UK Centre for Childhood Cancer Survivor Studies University of Birmingham College of Medical and Dental Sciences Institute of Applied Health Research Birmingham B15 2TT UK

Summary

Background

There are limited data on the risks of obstetric complications among survivors of adolescent and young adult cancer with most previous studies only reporting risks for all types of cancers combined. The aim of this study was to quantify deficits in birth rates and risks of obstetric complications for female survivors of 17 specific types of adolescent and young adult cancer.

Methods

The Teenage and Young Adult Cancer Survivor Study (TYACSS)—a retrospective, population-based cohort of 200 945 5-year survivors of cancer diagnosed at age 15–39 years from England and Wales—was linked to the English Hospital Episode Statistics (HES) database from April 1, 1997, to March 31, 2022. The cohort included 17 different types of adolescent and young adult cancers. We ascertained 27 specific obstetric complications through HES among 96 947 women in the TYACSS cohort. Observed and expected numbers for births and obstetric complications were compared between the study cohort and the general population of England to identify survivors of adolescent and young adult cancer at a heighted risk of birth deficits and obstetric complications relative to the general population.

Findings

Between April 1, 1997, and March 31, 2022, 21 437 births were observed among 13 886 female survivors of adolescent and young adult cancer from England, which was lower than expected (observed-to-expected ratio: 0·68, 95% CI 0·67–0·69). Other survivors of genitourinary, cervical, and breast cancer had under 50% of expected births. Focusing on more common (observed ≥100) obstetric complications that were at least moderately in excess (observed-to-expected ratio ≥1·25), survivors of cervical cancer were at risk of malpresentation of fetus, obstructed labour, amniotic fluid and membranes disorders, premature rupture of membranes, preterm birth, placental disorders including placenta praevia, and antepartum haemorrhage. Survivors of leukaemia were at risk of preterm delivery, obstructed labour, postpartum haemorrhage, and retained placenta. Survivors of all other specific cancers had no more than two obstetric complications that exceeded an observed-to-expected ratio of 1·25 or greater.

Interpretation

Survivors of cervical cancer and leukaemia are at risk of several serious obstetric complications; therefore, any pregnancy should be considered high-risk and would benefit from obstetrician-led antenatal care. Despite observing deficits in birth rates across all 17 different types of adolescent and young adult cancer, we provide reassurance for almost all survivors of adolescent and young adult cancer concerning their risk of almost all obstetric complications. Our results provide evidence for the development of clinical guidelines relating to counselling and surveillance of obstetrical risk for female survivors of adolescent and young adult cancer.

Funding

Children with Cancer UK, The Brain Tumour Charity, and Academy of Medical Sciences.

Le texte complet de cet article est disponible en PDF.

Plan


© 2024  The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 25 - N° 8

P. 1080-1091 - août 2024 Retour au numéro
Article précédent Article précédent
  • Celiac plexus radiosurgery for pain management in advanced cancer: a multicentre, single-arm, phase 2 trial
  • Yaacov R Lawrence, Marcin Miszczyk, Laura A Dawson, Dayssy Alexandra Diaz Pardo, Artur Aguiar, Dror Limon, Raphael M Pfeffer, Michael Buckstein, Aisling S Barry, Tikva Meron, Adam P Dicker, Jerzy Wydmański, Camilla Zimmermann, Ofer Margalit, David Hausner, Ofir Morag, Talia Golan, Galia Jacobson, Sergey Dubinski, Teo Stanescu, Ronen Fluss, Laurence S Freedman, Maoz Ben-Ayun, Zvi Symon
| Article suivant Article suivant
  • Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial
  • Xin Liu, Xiaowei Zhang, Shiyu Jiang, Miao Mo, Qifeng Wang, Yanli Wang, Liangping Zhou, Silong Hu, Huijuan Yang, Yifeng Hou, Yong Chen, Xueguan Lu, Yu Wang, Xiaoyan Zhou, Wentao Li, Cai Chang, Xiujiang Yang, Ke Chen, Jun Cao, Qinghua Xu, Yifeng Sun, Jianfeng Luo, Zhiguo Luo, Xichun Hu

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.